TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16894411

Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at rest (examination I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at stress (examination I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at rest (examination II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at stress (examination II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of EDV at rest and stress between examination I and II
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of ESV at rest and stress between examination I and II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at rest (examination I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at stress (examination I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at rest (examination II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at stress (examination II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation between LVEF at rest and stress (examination I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation between LVEF at rest and stress (examination II)
Number of subjects: 20
Study: 14692928

Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) at weekly intervals for 12 weeks
Number of subjects: 28
Study: 10480608

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment (HOMA) using immunoreactive insulin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous infusion of glucose with model assessment (CIGMA) using immunoreactive insulin
Number of subjects: 24

Group type: COMPARATOR
Intervention: First-phase intravenous glucose tolerance test (FSIVGTT)
Number of subjects: 24
Study: 8942885

Group type: EXPERIMENTAL
Intervention: Topical metronidazole applied to the lid margin in one eye
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lid hygiene alone in the fellow eye (Control)
Number of subjects: 10
Study: 1962619

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms bid
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 6127966

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (0.77%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Local anaesthetic, oxybuprocain
Number of subjects: 15
Study: 31450987

Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterolateral (PL) approach
Number of subjects: 100
Study: 30167782

Group type: EXPERIMENTAL
Intervention: 60 mg/day adjunctive raloxifene
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28089366

Group type: EXPERIMENTAL
Intervention: Six-times weekly in-center hemodialysis for an average of 14.6 hours
Number of subjects: 83

Group type: COMPARATOR
Intervention: Three-times weekly in-center hemodialysis for an average of 10.9 hours
Number of subjects: 83
Study: 25302927

Group type: EXPERIMENTAL
Intervention: GOS-supplemented formula (0.4 g/100 mL)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: GOS-supplemented formula
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 362
Study: 22689395

Group type: EXPERIMENTAL
Intervention: Topical microemulsion containing metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial gel product
Number of subjects: 0
Study: 20503132

Group type: EXPERIMENTAL
Intervention: Neck Vibration (NV) for 20 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Neck Vibration (NV) and Prism Adaptation (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neck Vibration (NV) only
Number of subjects: 0
Study: 17661241

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cyanoacrylate
Number of subjects: 72
Study: 16235062

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (400 microg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11919121

Group type: EXPERIMENTAL
Intervention: Diet alone (30 kcal/kg per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet with voglibose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet with glyburide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 36
Study: 10362186

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8720210

Group type: EXPERIMENTAL
Intervention: 90‐mu F capacitance
Number of subjects: 16

Group type: COMPARATOR
Intervention: 120‐mu F capacitance
Number of subjects: 16
Study: 1828205

Group type: EXPERIMENTAL
Intervention: Amoxycillin plus lactobacilli
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 40
Study: 7050714

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) 160 mg of TMP and 800 mg of SMX
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) alone 200 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 30970056

Group type: EXPERIMENTAL
Intervention: Homeopathic therapy (including Berberis, Mercurius solubilis/Belladonna/Hepar sulphur, and Pyrogenium)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) + Homeopathic therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study: 29974280

Group type: EXPERIMENTAL
Intervention: He-Ne laser and topical treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical treatment only
Number of subjects: 15
Study: 27215244

Group type: EXPERIMENTAL
Intervention: Na/K citrate
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 210
Study: 24699061

Group type: EXPERIMENTAL
Intervention: Losmapimod (7.5 mg BD) for 6 weeks
Number of subjects: 152
Study: 22036832

Group type: EXPERIMENTAL
Intervention: Chlorhexidine cloths
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing methods
Number of subjects: 0
Study: 19560322

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) 3, 6, 9, or 12 mg
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study: 17761460

Group type: EXPERIMENTAL
Intervention: Combination therapy with dutasteride and tamsulosin
Number of subjects: 4838

Group type: COMPARATOR
Intervention: Monotherapy with dutasteride
Number of subjects: 4838

Group type: COMPARATOR
Intervention: Monotherapy with tamsulosin
Number of subjects: 4838
Study: 18193707

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 1001
Study: 15161956

Group type: EXPERIMENTAL
Intervention: MMF/reduced dose cyclosporin (0.5-1.0 g bd; C(0): 75-100 ng/ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tacrolimus for cyclosporin (C(0): 5-10 ng/ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuation of standard therapy (C(0): 163 ng/ml (145-215 ng/ml))
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MMF/reduced dose cyclosporin
Number of subjects: 42
Study: 10627347

Group type: EXPERIMENTAL
Intervention: Intravenous regional analgesia preoperatively
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intra-articular analgesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 36
Study: 9010696

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1458772

Group type: COMPARATOR
Intervention: 0, 7.5, 15, and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0, 15, and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg nicotine via nasal spray
Number of subjects: 36

Group type: COMPARATOR
Intervention: 15 and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36
Study: 6233150

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) 20 mg twice a day for 2 weeks, then aminoglutethimide (AG) 250 mg four times a day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) plus aminoglutethimide (AG) from day 1
Number of subjects: 28
Study: 31437472

Group type: EXPERIMENTAL
Intervention: 2 red/2 green TLL (2 negative/2 positive) food item with sugar labeled green
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low energy content food items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High energy content food items
Number of subjects: 0
Study: 30098353

Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0 to 7 days (n = 675)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (n = 655)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Tissue from donors with diabetes
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Operative complications
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of PACE
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Preoperative donor endothelial cell density
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Graft diameter
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Injector use for graft insertion
Number of subjects: 1090
Study: 26974440

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24202061

Group type: EXPERIMENTAL
Intervention: High-impact exercise (intervention group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham exercise (control group)
Number of subjects: 96
Study: 22935601

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops
Number of subjects: 90

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 90
Study: 19279298

Group type: EXPERIMENTAL
Intervention: Relative risk reduction (RRR) information
Number of subjects: 113

Group type: COMPARATOR
Intervention: Absolute risk reduction (ARR) information
Number of subjects: 113
Study: 17448832

Group type: EXPERIMENTAL
Intervention: CO(2) laser vaporization
Number of subjects: 82
Study: 16329060

Group type: EXPERIMENTAL
Intervention: Posterior sub-tenon injection of triamcinolone acetonide (TA), 40 mg, repeated after 2 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (subconjunctival injection), repeated after 2 months
Number of subjects: 64
Study: 12547661

Group type: EXPERIMENTAL
Intervention: 20-mcg oral contraceptive (OC)
Number of subjects: 43
Study: 9653611

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg thrice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 90
Study: 8145275

Group type: EXPERIMENTAL
Intervention: Gail et al. model for predicting breast cancer risk
Number of subjects: 115172
Study: 2687691

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.07 U/kg body weight, subcutaneously at bedtime
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 4629980

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (D.S.C.G.)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Inactive preparation (placebo)
Number of subjects: 117
Study: 30611286

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 115

Group type: COMPARATOR
Intervention: Exergame training
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Active control (relaxation and flexibility exercises)
Number of subjects: 115
Study: 28192113

Group type: EXPERIMENTAL
Intervention: 60 mg levodropropizine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 mg dihydrocodeine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study: 24711062

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 22
Study: 24326106

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I, n = 106)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by disease activity criteria (group II, n = 116)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (vPDT) (group III, n = 55)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by disease activity criteria (group II)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) (group I)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) (group II)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (vPDT) (group III)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (both groups I and II)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 277
Study: 21993470

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fellow eye control
Number of subjects: 69
Study: 19664345

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (TB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral mefenamic acid and intramuscular meperidine (M&M)
Number of subjects: 12
Study: 17500380

Group type: EXPERIMENTAL
Intervention: Metronidazole gel 0.75%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Azelaic acid gel 15%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metronidazole gel 1%
Number of subjects: 36
Study: 15841781

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride gel (Group 2)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Simple lubrication (Group 1)
Number of subjects: 172
Study: 12744480

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.05 mg/kg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 10482998

Group type: EXPERIMENTAL
Intervention: CD44s expression
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Incorporation of CD44s in the IPI parameter 'stage'
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: CD44v6 expression
Number of subjects: 276
Study: 7489600

Group type: EXPERIMENTAL
Intervention: 40cc IAB at assist ratio 1:1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 32cc IAB at assist ratio 1:1
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40cc IAB at assist ratio 1:8
Number of subjects: 20

Group type: COMPARATOR
Intervention: 32cc IAB at assist ratio 1:8
Number of subjects: 20
Study: 1784030

Group type: EXPERIMENTAL
Intervention: Ribavirin therapy (200 mg four times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7223696

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation from 6 months to 3 years
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during the 3rd trimester of pregnancy and the first 6 months of the child's life
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation throughout the entire study period
Number of subjects: 433

Group type: COMPARATOR
Intervention: Maternal education program without nutritional supplement
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Both nutritional supplementation and maternal education program
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 433
Study: 31551213

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU weekly for 12 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 28396556

Group type: EXPERIMENTAL
Intervention: Treatment for STIs during pregnancy
Number of subjects: 615

Group type: COMPARATOR
Intervention: No treatment for STIs during pregnancy (control group)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Genital HSV-2 shedding
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Untreated curable STIs (T.vaginalis, C.trachomatis, N.gonorrhoea)
Number of subjects: 615
Study: 27072817

Group type: EXPERIMENTAL
Intervention: Enhanced web-based weight loss program with individualized feedback and reminders
Number of subjects: 301

Group type: COMPARATOR
Intervention: Basic web-based weight loss program with limited feedback and reminders
Number of subjects: 301
Study: 25186121

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Family support (FS)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 167
Study: 22287681

Group type: EXPERIMENTAL
Intervention: Dried distillers grains (DDG) supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steam-flaked corn based diet (SFC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dried distillers grains (DDG) at 35% DM in steam-flaked corn-based finishing diets
Number of subjects: 60
Study: 19783590

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 0
Study: 17223915

Group type: EXPERIMENTAL
Intervention: Karyotypic abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Chromosome 1p abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Chromosome 1q abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Chromosome 13 abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Complex abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Hypodiploidy
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Chromosome 1p and/or 1q abnormalities
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Deletion of chromosome 13 or 13q
Number of subjects: 453
Study: 15015148

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (50 minutes of treadmill walking at 70% VO2max)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No exercise (control trial)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 18
Study: 12113669

Group type: EXPERIMENTAL
Intervention: Hyperthermal dilute lipiodol embolization
Number of subjects: 131

Group type: COMPARATOR
Intervention: Chemoembolization (lipiodol-epirubicin emulsion)
Number of subjects: 131
Study: 9223883

Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine) applied for 30 min, 60 min, and 120 min before venous cannulation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine) applied for 120 min
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine tape (3 X 5 cm, 18 mg of lidocaine)
Number of subjects: 135
Study: 8462537

Group type: EXPERIMENTAL
Intervention: 30 mg nicomorphine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 20 mg nicomorphine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 10 mg nicomorphine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nicomorphine and its metabolites
Number of subjects: 3
Study: 2829262

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 30828929

Group type: EXPERIMENTAL
Intervention: BioChaperone glargine lispro co-formulation (BC Combo)
Number of subjects: 39
Study: 28482406

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (2-3 times)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conservative treatment alone (Control)
Number of subjects: 97
Study: 25557141

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25139116

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin and metronidazole (AMX-MET) during non-surgical treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin and metronidazole (AMX-MET)
Number of subjects: 41
Study: 22325128

Group type: EXPERIMENTAL
Intervention: High levels of depressive symptoms
Number of subjects: 5362

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate levels of depressive symptoms
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Low levels of depressive symptoms
Number of subjects: 5362
Study: 19185083

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study: 18094377

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Standard-dose cyclosporine
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Low-dose cyclosporine
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Low-dose sirolimus
Number of subjects: 1645
Study: 15216449

Group type: EXPERIMENTAL
Intervention: Moxonidine (MOX) 0.2 - 0.6 mg/d
Number of subjects: 200

Group type: COMPARATOR
Intervention: Metoprolol (MET) 50 - 150 mg/d
Number of subjects: 200
Study: 11791642

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AM, n = 40)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR, n = 38)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (PL, n = 40)
Number of subjects: 118
Study: 9754991

Group type: EXPERIMENTAL
Intervention: Oral tolcapone (200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous tolcapone (50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous tolcapone
Number of subjects: 16